A Phase 2 clinical trial involving degarelix, titled "ETHAN - ET for Male BC," was listed as recruiting as of August 24, 2026. The trial, registered under identifier NCT05501704, is evaluating endocrine therapy in male breast cancer. According to the ClinicalTrials.gov listing, the study status is recruiting and the phase is Phase 2. No results have been posted for this trial at this time. The listing does not provide additional details on trial design, endpoints, or enrollment numbers beyond status and phase. This update reflects only the recruitment status as recorded in the trial registry and does not indicate any outcomes or efficacy findings. Degarelix is an approved compound, and this trial represents an investigational use being studied in the context of male breast cancer. Readers interested in the study can review the official registry listing for further protocol details as they become available. For more background on degarelix, including its approved uses and general profile, readers can consult the compound overview.
Degarelix Trial "ETHAN" for Male Breast Cancer Recruiting, Phase 2
See the full degarelix overview
Source: https://clinicaltrials.gov/study/NCT05501704